The pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab.
Today (Tuesday 22 October) the pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab.
Hilary Evans, Chief Executive at Alzheimer’s Research UK, said:
“People affected by Alzheimer’s have waited a long time for a life-changing new treatment and this exciting announcement offers new hope that one could be in sight.
“Taking another look at aducanumab is a positive step for all those who took part in the clinical trials and the worldwide dementia research community. As more data emerges, we hope it will spark global discussions about the next steps for delivering much-needed treatments into people’s hands.
“The FDA will now assess the new data and its strengths and limitations before deciding about whether aducanumab should be made widely available in the US. At Alzheimer’s Research UK, we are already bringing together regulators and drug developers to help speed up the delivery of promising new treatments towards patients. This important work now has renewed urgency.
“It’s only through a sustained commitment to dementia research that will we make breakthroughs possible that keep people connected to their families, their worlds and themselves for longer.”
Ends
For further information, or to speak with Hilary Evans, please contact Ed Pinches, Communications Officer at Alzheimer’s Research UK on 0300 111 5 666, mobile or email press@alzheimersresearchuk.org
Notes to editors:
· Our animation “What is dementia?” explains the essentials of dementia and the diseases that cause it https://www.youtube.com/watch?
· Alzheimer’s Research UK is the UK’s leading charity specialising in finding preventions, treatments and a cure for dementia.
· To help make breakthroughs possible, donate today by visiting www.alzheimersresearchuk.org or calling 0300 111 5555.
· We are currently supporting pioneering dementia research projects worth nearly £34 million in leading Universities across the UK.
· How can we challenge perceptions of dementia using only an orange? Find out more at www.alzheimersresearchuk.org/
